StockNews.AI
ATOS
StockNews.AI
7 hrs

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

1. Atossa's (Z)-endoxifen data accepted for presentation at SABCS 2025. 2. Four presentations planned, focusing on breast cancer treatment advancements. 3. Clinical evidence continues to grow, potentially enhancing market positioning. 4. Atossa emphasizes disciplined resource allocation for future regulatory submissions. 5. Forward-looking statements highlight risks like regulatory outcomes and funding.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentations can build credibility leading to positive market sentiment. Historical examples show that successful data reveals often lead to stock price gains.

How important is it?

The article discusses significant advancements in treatment, crucial for ATOS's long-term growth in oncology markets.

Why Long Term?

Research outcomes anticipated in 2025 may enhance ATOS's future revenue streams. Successful trials typically translate to longer-term stock appreciation.

Related Companies

GILDNVDABMY
Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention , /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX. "We continue to add to our body of clinical evidence. At SABCS 2025, we look forward to four poster presentations highlighting findings from studies evaluating the use of (Z)-endoxifen to advance breast cancer treatment and prevention," said Dr. Steven Quay, Atossa Therapeutics President and Chief Executive Officer. Poster Presentation Details: Title: Initial results from RECAST DCIS: Multicenter platform trial testing activesurveillance and novel endocrine therapy agents for DCIS management Date/Time:  Thursday, December 11, 2025, 12:30pm - 2:00pm CT  Title: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot Date/Time: Thursday, December 11, 2025, 12:30pm - 2:00pm CT  Title: (Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants viaInactive Conformation Stabilization and Reversal of Mutant ESR1-AssociatedTranscriptional Signatures Date/Time:  Friday, December 12, 2025, 7:00am - 8:30am CT  Title: A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment forPremenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE) Date/Time:  Friday, December 12, 2025, 12:30pm - 2:00pm CT  About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative therapies for significant unmet needs in breast cancer. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. For more information, visit www.atossatherapeutics.com and refer to Atossa's filings with the U.S. Securities and Exchange Commission (SEC). Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding Atossa's commercial readiness, financing strategy, operational plans, and the development and potential commercialization of (Z)-endoxifen. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including market conditions, regulatory outcomes, clinical results, manufacturing and supply, intellectual-property challenges, and the Company's ability to secure sufficient funding on acceptable terms. For a discussion of risks and uncertainties, please refer to Atossa's filings with the U.S. Securities and Exchange Commission. Atossa undertakes no obligation to update forward-looking statements, except as required by law. SOURCE Atossa Therapeutics Inc

Related News